TibaRay has launched a Regulation CF campaign on Wefunder, opening the company to individual investors as it continues developing next generation accelerator technology designed to enable FLASH radiotherapy. The company, based in Fremont, California, aims to cure cancer in a FLASH by enabling radiation to be delivered hundreds of times faster than current systems. Research suggests that ultrafast radiation delivery, known as FLASH radiotherapy, may reduce damage to healthy tissue while maintaining tumor control, requiring fundamentally new accelerator technology.
TibaRay is a Stanford spinout built on decades of accelerator physics and medical physics research. To date, more than $27 million has been invested in the development of its technology, including over $14 million in non-dilutive federal research grants. The company's intellectual property portfolio includes more than 20 issued and pending patents related to next generation radiotherapy systems.
Its proprietary Galactica linear accelerator has already been designed into Leo Cancer Care's upright radiotherapy system, marking the company's first commercial integration of its accelerator platform. TibaRay is pursuing a phased commercialization strategy. In the near term, the company generates revenue by commercializing its accelerator technology across medical and adjacent markets including imaging, security scanning, and non-destructive testing. The long term objective is deployment of the PHASER radiotherapy system designed to enable ultrafast treatment delivery.
The Wefunder campaign allows individual investors to participate in this next phase of development. Investors can review the full opportunity, including technology details, partnerships, and development plans on the TibaRay campaign page on Wefunder. The original press release is available on NewMediaWire.
This announcement is important because it opens the door for individual investors to support a technology that could revolutionize cancer treatment. FLASH radiotherapy has the potential to significantly reduce side effects from radiation therapy by sparing healthy tissue, which could improve patient outcomes and quality of life. TibaRay's progress, backed by substantial federal grants and a strong patent portfolio, positions it as a key player in bringing this technology to market.
